Skip to content
HowShorted

CRISPR Therapeutics AG short interest in 2023

In 2023, CRISPR Therapeutics AG's disclosed short interest ran from 12.62% of shares outstanding on 13 Jan 2023 to 20.46% on 29 Dec 2023, a change of +7.84 percentage points. The year's high was 21.81% on 15 Dec 2023 and its low 12.62% on 13 Jan 2023, averaging 16.57% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.33 days on 15 Sep 2023. Full history: CRISPR Therapeutics AG.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CRISPR Therapeutics AG in 2023

2023 in figures

Start of year
12.62% (13 Jan 2023)
End of year
20.46% (29 Dec 2023)
Change
+7.84 pp
High
21.81% (15 Dec 2023)
Low
12.62% (13 Jan 2023)
Average
16.57%
Highest days to cover
17.33 (15 Sep 2023)
SEC filings marked
8

Every report in 2023

CRISPR Therapeutics AG short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202312.62%8.54
31 Jan 202312.75%10.46
15 Feb 202313.09%9.37
28 Feb 202314.26%8.0510-K filed, results (8-K)
15 Mar 202315.55%12.85
31 Mar 202316.22%13.44
14 Apr 202316.53%8.67
28 Apr 202316.86%10.78
15 May 202315.75%6.7410-Q filed, results (8-K)
31 May 202315.45%9.84
15 Jun 202315.80%8.65
30 Jun 202315.93%11.55
14 Jul 202315.59%13.82
31 Jul 202315.34%13.06
15 Aug 202316.88%10.9310-Q filed, results (8-K)
31 Aug 202317.74%15.89
15 Sep 202317.36%17.33
29 Sep 202316.42%15.45
13 Oct 202317.07%11.76
31 Oct 202317.49%9.09
15 Nov 202320.61%5.6910-Q filed, results (8-K)
30 Nov 202320.05%4.58
15 Dec 202321.81%3.61
29 Dec 202320.46%6.80

See also: CRISPR Therapeutics AG's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.